1. |
Wang X, Zhang Z, Wu SC. Health Benefits of Silybum marianum: Phytochemistry, Pharmacology, and
Applications. J Agric Food Chem. 68, 11644-11664 (2020)
|
2. |
Emadi SA, Ghasemzadeh Rahbardar M, Mehri S, Hosseinzadeh H. A review of therapeutic potentials of
milk thistle (Silybum marianum L.) and its main constituent, silymarin, on cancer, and their related
patents. Iran J Basic Med Sci. 25, 1166-1176 (2022)
|
3. |
Dietz BM, Hajirahimkhan A, Dunlap TL, Bolton JL. Botanicals and Their Bioactive Phytochemicals for
Women's Health. Pharmacol Rev. 68, 1026-1073 (2016)
|
4. |
Inman JL, Bissell MJ. Apical polarity in three-dimensional culture systems: where to now? J Biol.
9, 2 (2010)
|
5. |
Fujisaki H, Hattori S. Keratinocyte apoptosis on type I collagen gel caused by lack of laminin
5/10/11 deposition and Akt signaling. Exp Cell Res. 280, 255-269 (2002)
|
6. |
Fujisaki H, Futaki S. Epithelial-Mesenchymal Transition Induced in Cancer Cells by Adhesion to Type
I Collagen. Int J Mol Sci. 24, 198 (2023)
|
7. |
Huang Y, Wang Y, Tang J, Qin S, Shen X, He S, Ju S. CAM-DR: Mechanisms, Roles and Clinical
Application in Tumors. Front Cell Dev Biol. 9, 698047 (2021)Jansen KA, Atherton P, Ballestrem C.
Mechanotransduction at the cell-matrix interface. Semin Cell Dev Biol. 71, 75-83 (2017) |
8. |
Křen V. Chirality Matters: Biological Activity of Optically Pure Silybin and Its Congeners. Int J
Mol Sci. 22, 7885 (2021)
|
9. |
Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt/β-catenin signaling by
suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal.
24, 2291-2296 (2012)
|
10. |
Si L, Fu J, Liu W, Hayashi T, Nie Y, Mizuno K, Hattori S, Fujisaki H, Onodera S, Ikejima T.
Silibinin inhibits migration and invasion of breast cancer MDA-MB-231 cells through induction of
mitochondrial fusion. Mol Cell Biochem. 463, 189-201 (2020)
|
11. |
Kauntz H, Bousserouel S, Gosse F, Marescaux J, Raul F. Silibinin, a natural flavonoid, modulates
the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis.
Int J Oncol. 41, 849-854 (2012)
|
12. |
Xu S, Zhang H, Wang A, Ma Y, Gan Y, Li G. Silibinin suppresses epithelial-mesenchymal transition in
human non-small cell lung cancer cells by restraining RHBDD1. Cell Mol Biol Lett. 25, 36 (2020)
|
13. |
Prasad RR, Paudel S, Raina K, Agarwal R. Silibinin and non-melanoma skin cancers. J Tradit
Complement Med. 10, 236-244 (2020)
|
14. |
Kumar R, Deep G, Agarwal R. An Overview of Ultraviolet B Radiation-Induced Skin Cancer
Chemoprevention by Silibinin. Curr Pharmacol Rep. 1, 206-215 (2015)
|
15. |
Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin
in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med. nep164 (2011)
|
16. |
Yang J, Sun Y, Xu F, Liu W, Mai Y, Hayashi T, Hattori S, Ushiki-Kaku Y, Onodera S, Tashiro SI,
Ikejima T. Silibinin ameliorates amylin-induced pancreatic beta-cell apoptosis partly via
upregulation of GLP-1R/PKA pathway. Mol Cell Biochem. 452, 83-94 (2019)
|
17. |
Liu P, Wang C, Chen W, Kang Y, Liu W, Qiu Z, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T.
Inhibition of GluN2B pathway is involved in the neuroprotective effect of silibinin on
streptozotocin-induced Alzheimer's disease models. Phytomedicine. 109, 154594 (2023)
|
18. |
Liu X, Liu W, Wang C, Chen Y, Liu P, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T.
Silibinin attenuates motor dysfunction in a mouse model of Parkinson's disease by suppression of
oxidative stress and neuroinflammation along with promotion of mitophagy. Physiol Behav. 239, 113510
(2021)
|
19. |
Liu X, Chen W, Wang C, Liu W, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima T. Silibinin
ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated
with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation. Physiol Behav. 241,
113593 (2021)
|
20. |
Liu WW, Wang F, Li C, Otkur W, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Onodera S, Ikejima T.
Silibinin treatment protects human skin cells from UVB injury through upregulation of estrogen
receptors. J Photochem Photobiol B. 216, 112147 (2021)
|
21. |
Liu WW, Wang F, Li C, Song XY, Otkur W, Zhu YY, Hayashi T, Mizuno K, Hattori S, Fujisaki H, Ikejima
T. Silibinin relieves UVB-induced apoptosis of human skin cells by inhibiting the YAP-p73 pathway.
Acta Pharmacol Sin. 43, 2156-2167 (2022)
|
22. |
Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK. Sex hormones and sex
hormone-targeting therapies in systemic sclerosis: A systematic literature review. Semin Arthritis
Rheum. 50, 140-148 (2020)
|
23. |
Hewitt SC, Korach KS. Estrogen Receptors: New Directions in the New Millennium. Endocr Rev. 39,
664-675 (2018)
|
24. |
Downward J, Basu S. YAP and p73: a complex affair. Mol Cell. 32, 749-750 (2008)
|
25. |
Liu B, Liu W, Liu P, Liu X, Song X, Hayashi T, Onodera S, Ikejima T. Silibinin Alleviates the
Learning and Memory Defects in Overtrained Rats Accompanying Reduced Neuronal Apoptosis and
Senescence. Neurochem Res. 44, 1818-1829 (2019)
|